Abstract:Background: Gastrointestinal immune-related adverse events are frequently caused by immune checkpoint inhibitors (ICIs) and often require interruption of cancer treatment. Compared with ICI colitis and enteritis, limited information exists about ICI gastritis. This study characterized clinical features and treatment outcomes of ICI gastritis. Methods: Consecutive cancer patients who received ICIs and underwent endoscopy with gastric biopsies while on ICIs from 2011 to 2021 were retrospectively assessed. Specific histopathologic features identified ICI gastritis. Results: Of 6450 ICI-treated patients, 162 (2.5%) underwent endoscopy with gastric biopsies. ICI gastritis was identified in 54 (33%) biopsied patients; 38 (70%) had concurrent ICI enteritis/colitis and 16 (30%) had isolated ICI gastritis. Dyspepsia (38%) and bloating (25%) were the most frequent symptoms of isolated ICI gastritis. Compared with patients with concomitant enteritis/colitis, patients with isolated gastritis were less likely to have diarrhea (13% vs 68%; p < .001) or abdominal pain (19% vs 47%; p = .07). Patients with isolated ICI gastritis less frequently required glucocorticoids (69% vs 92%; p = .04) and had lower incidence of ICI hold/withdrawal (13% vs 42%; p = .06). There was no association between severity or extent of luminal inflammation and antitumor response (p = .85 and p = .44, respectively). Endoscopically, gastric mucosa appeared normal in 11 (20%) patients with biopsy-proven ICI gastritis. Conclusion: ICI gastritis may present alone or more commonly with concurrent enteritis/colitis, which may differentiate its clinical course. Gastric biopsies are required to diagnose a substantial minority of endoscopically normal, clinically significant cases. Most patients with isolated gastritis can continue ICI therapy uninterrupted, but a notable proportion require glucocorticoids. Plain language summary: Immune checkpoint inhibitors are effective anticancer treatments, but can cause inflammatory toxicities, including of the stomach (gastritis), intestine, and colon. Limited information is available on gastritis triggered by these agents. Adult patients with cancer who were treated with immune checkpoint inhibitors and had an upper gastrointestinal endoscopy with biopsies of the stomach were examined. More than two-thirds (70%) of people with checkpoint inhibitor gastritis also had inflammatory changes of the small intestine and/or colon. Compared with patients with isolated checkpoint gastritis, the subgroup with concomitant enteritis/colitis more frequently had abdominal pain, diarrhea, needed steroids, and/or needed to pause or stop antitumor therapy.

S3946 Gut on Fire: Immune Checkpoint Inhibitor-Induced Gastrointestinal Inflammation

S5147 Steroid Refractory Immune Checkpoint Inhibitor Induced Severe Gastritis Responsive to Infliximab

S3034 Refractory Immune Checkpoint Inhibitor-Associated Colitis: Case Report

S1161 Gastrointestinal Infection Prior to Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk for Checkpoint-Inhibitor Colitis

Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course

Immune checkpoint inhibitor therapy associated enteritis mimicking celiac disease

S1487 Multiple Gastrointestinal Immune Related Adverse Events From Immune Checkpoint Inhibitor Therapy

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Checkpoint Inhibitor-Induced Colitis: An Update

Immune checkpoint inhibitor-induced diarrhea and colitis: an overview

A Case of Immune Checkpoint Inhibitor-Induced Duodenitis

P001 Immune Checkpoint Inhibitor-Induced Colitis is Mediated by Polyfunctional Lymphocytes and is Dependent on the IL23/IFNg Axis

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases

Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report

Isolated Immune Checkpoint Inhibitor-Induced Gastritis Leading to Gastrocolic Fistula Formation

Immune checkpoint inhibitor induced colitis and arthritis: A case report

Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis

Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: a case report and literature review